The Research of French PaRole OncO : A Peer Supported Program for Cancer Patients

NCT ID: NCT06817655

Last Updated: 2025-02-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

720 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-15

Study Completion Date

2027-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Peer support is a valuable mode of accompaniment between individuals who are facing or have faced similar challenging life experiences. In this context, a patient advisor (PA) shares their experiential knowledge, derived from living with a disease, to offer emotional, experiential, and informational support to other patients. This PA intervention represents an innovative form of support for oncology patients, potentially addressing their needs more comprehensively throughout the care pathway by integrating psychosocial dimensions into the support approach.

The present pilot study aims to investigate the implementation and effectiveness of the peer-to-peer support program "PaRole OncO France" in the oncology setting. The study will focus on:

1. Evaluating clinical and psychosocial parameters
2. Utilizing an in-depth multiple case study approach This research seeks to provide insights into how peer support can enhance the overall care experience for oncology patients, potentially leading to improved patient outcomes and a more holistic approach to cancer care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Peer support is a valuable mode of accompaniment between individuals who are facing or have faced similar challenging life experiences. In this context, a patient advisor (PA) shares their experiential knowledge, derived from living with a disease, to offer emotional, experiential, and informational support to other patients. This PA intervention represents an innovative form of support for oncology patients, potentially addressing their needs more comprehensively throughout the care pathway by integrating psychosocial dimensions into the support approach.

The present pilot study aims to investigate the implementation and effectiveness of the peer-to-peer support program "PaRole OncO France" in the oncology setting. The study will focus on:

1. Evaluating clinical and psychosocial parameters
2. Utilizing an in-depth multiple case study approach This research seeks to provide insights into how peer support can enhance the overall care experience for oncology patients, potentially leading to improved patient outcomes and a more holistic approach to cancer care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

The intervention consists of patient accompaniment by patient advisors. At least one patient advisor is recruited in each service participating in the study. Patients will be paired with patient advisor and can benefit from accompaniment during their hospital stays or remotely (by phone). The patient advisor will, in turn, be supported by the healthcare professionals' team as well as through a community of practice.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supportive care (PaRole OncO France program)

Patients participate in the PaRole OncO France program for which they are matched with a patient advisor and followed throughout treatment in person and/or phone.

Group Type EXPERIMENTAL

PaRole OncO France : Individual peer support

Intervention Type BEHAVIORAL

Following the development of the peer support program "PaRole OncO France", we are now proceeding with its implementation and evaluation through a pilot study. This study aims to derive both implementation-related and clinically relevant results.

Prior to their assignment, all peer helpers undergo a comprehensive training course to ensure they are well-equipped for their role.

Patients receive individual peer support during their treatment visits, providing real-time assistance and support within the clinical setting.

The study incorporates three key measurement time points:

1. Baseline measurement (before the intervention)
2. After the intervention
3. Follow-up measurement (1months after the first intervention)
4. Follow-up measurement (6 months after the first intervention)

At each time points, participants will complete a set of standardized questionnaires. These instruments are designed to capture relevant outcomes and experiences related to the peer support intervention.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PaRole OncO France : Individual peer support

Following the development of the peer support program "PaRole OncO France", we are now proceeding with its implementation and evaluation through a pilot study. This study aims to derive both implementation-related and clinically relevant results.

Prior to their assignment, all peer helpers undergo a comprehensive training course to ensure they are well-equipped for their role.

Patients receive individual peer support during their treatment visits, providing real-time assistance and support within the clinical setting.

The study incorporates three key measurement time points:

1. Baseline measurement (before the intervention)
2. After the intervention
3. Follow-up measurement (1months after the first intervention)
4. Follow-up measurement (6 months after the first intervention)

At each time points, participants will complete a set of standardized questionnaires. These instruments are designed to capture relevant outcomes and experiences related to the peer support intervention.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient participants :

* Patients with newly diagnosed or recurrent cancer (urological, digestive, mammary, pulmonary, ORL, peritoneal carcinosis, melanoma, oncohaematology)
* French-speaking patients
* Patients adivsors :

* Patient advisors will be past cancer patients not currently undergoing treatment for their cancer, and considered without evidence of disease
* French-speaking patients

Exclusion Criteria

* Patients participants :

* Not followed in one of the participating units
* Persons deprived of their liberty by judicial or administrative decision
* Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
* Patient advisors :

* Recurrence of the disease
* Currently undergoing treatment for active cancer
Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospices Civils de Lyon

Lyon, , France

Site Status

Hospices Civils de Lyon

Lyon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Juile HASEBAERT, PhD

Role: CONTACT

4.72.11.51.65 ext. +33

Anne TERMOZ

Role: CONTACT

04 27 85 63 00 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stéphane DALLE, MD

Role: primary

Sébastien COURAUD, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

69HCL23_1301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.